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Abstract
Common variation in the CYP2B6 gene, encoding the cytochrome P450 2B6
enzyme, is associated with substrate‐specific altered clearance of multiple drugs.
CYP2B6 is a minor contributor to hepatic nicotine metabolism, but the enzyme has
been proposed as relevant to nicotine‐related behaviors because of reported
CYP2B6 mRNA expression in human brain tissue. Therefore, we hypothesized that
CYP2B6 variants would be associated with altered nicotine oxidation, and that nico-
tine metabolism by CYP2B6 would be detected in human brain microsomes. We
generated recombinant enzymes in insect cells corresponding to nine common
CYP2B6 haplotypes and demonstrate genetically determined differences in nicotine
oxidation to nicotine iminium ion and nornicotine for both (S) and (R)‐nicotine.
Notably, the CYP2B6.6 and CYP2B6.9 variants demonstrated lower intrinsic clear-
ance relative to the reference enzyme, CYP2B6.1. In the presence of human brain
microsomes, along with nicotine‐N‐oxidation, we also detect nicotine oxidation to
nicotine iminium ion. However, unlike N‐oxidation, this activity is NADPH indepen-
dent, does not follow Michaelis‐Menten kinetics, and is not inhibited by NADP or
carbon monoxide. Furthermore, metabolism of common CYP2B6 probe substrates,
methadone and ketamine, is not detected in the presence of brain microsomes. We
conclude that CYP2B6 metabolizes nicotine stereoselectively and common CYP2B6
variants differ in nicotine metabolism activity, but did not find evidence of CYP2B6
activity in human brain.
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1 | INTRODUCTION
Tobacco consumption and liability to nicotine dependence are heri-
table traits.1,2 One clearly implicated pathway is the C‐oxidation of
nicotine to nicotine iminium ion and subsequently to cotinine by
CYP2A6, one of three nicotine metabolism pathways (Figure 1). Vari-
ation in nicotine C‐oxidation influences cigarette consumption
among dependent smokers and consequent disease risk. CYP2A6 is
responsible for 70%‐80% of nicotine metabolism in most people,3
and the mechanism of influence is straightforward: smokers with
reduced CYP2A6 function metabolize nicotine more slowly, delaying
the onset of the withdrawal symptoms that compel nicotine addicts
Abbreviations: CLint, intrinsic clearance; CYP, cytochrome P450; FMO, flavin-containing
monooxygenase; HBM, human brain microsomes; NADPH, nicotinamide adenine
dinucleotide phosphate; POR, P450 oxidoreductase; Vmax, maximum velocity.
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to reach for the next cigarette. Hence, polymorphisms in CYP2A6
causing slower nicotine metabolism are also associated with reduced
cigarette consumption and disease risk in multiple populations.4-7
Nicotine is also metabolized via two other major pathways: glu-
curonidation by UGT2B10, and oxidation to nicotine‐N‐oxide by the
flavin‐containing monooxygenases (FMOs). Variation in FMO3 is
associated with altered hepatic nicotine metabolism.8
CYP2B6 is a minor contributor to hepatic nicotine metabolism
with a Km approximately 10‐fold higher than that of CYP2A6.9
Genetic variation in the CYP2B6 locus has a small but clinically
insignificant influence on in vivo nicotine clearance in most sub-
jects,10,11 but may be important in CYP2A6 slow metabolizers.
CYP2B6 has also been reported to be expressed in human brain tis-
sue,12 unlike CYP2A6, and it has therefore been proposed that
genetic variation affecting the CYP2B6 enzyme might play a signifi-
cant role in nicotine‐related phenotypes.13 CYP2B6 is highly poly-
morphic, and common haplotypes, especially CYP2B6*6 and *9,
containing 516G>T (Q172H, minor allele frequency 26% in Euro-
pean Americans, 37% in African Americans (http://evs.gs.washing
ton.edu/EVS/)) are associated with clinically significantly altered
pharmacokinetics for different substrates, relative to the reference
allele.14-19 Because the effects of CYP2B6 polymorphisms on
CYP2B6 activity is substrate‐specific, activities of different CYP2B6
isoforms cannot be assumed for untested substrates, such as nico-
tine. Therefore, we have expressed polymorphic CYP2B6 enzymes
and measured their nicotine metabolism activity in vitro. We further
attempted to measure cytochrome P450‐mediated nicotine metabo-
lism in human brain microsomes, where FMO activity was previously
demonstrated,8,20 using nicotine and other CYP2B6 probe sub-
strates.
2 | MATERIALS AND METHODS
CYP2B6 variants, reference allele P450 oxidoreductase (POR), and
reference allele cytochrome b5 vectors were previously generated,
and recombinant proteins previously expressed in insect cells, as
described.17,21 Haplotype selection was based on the known clinical
significance and frequency of the polymorphism, and a desire to
inform the mechanistic basis for the influence of these polymor-
phisms on metabolism. There is growing evidence that the influence
of CYP2B6 polymorphisms varies between substrates, and may vary
between enantiomers of those substrates. For example, 516G>T
(Q172H) is a canonical single nucleotide polymorphism (SNP)
thought to result in diminished metabolism,17,21,22 while 785A>G
(K262R) alone causes increased activity for some but not all 2B6
substrates.21,23 To evaluate contribution from the two major SNPs,
we selected variants with various combinations of these mutations
(2B6*4, *6, *7, *9, *16, *19, *26) even though some are minor in pop-
ulation frequency. The other three 2B6 variants (*5, *17, *18) have
relatively high allele frequency.
Human brain microsomes were prepared as described8 from de‐
identified cerebral cortex flash‐frozen postmortem obtained from the
National Disease Research Interchange (NDRI), Philadelphia PA, USA.
They included four Caucasian males, one Caucasian female, and one
African American male with ages ranging from 58 to 90 years. None
were reported to be current smokers or substance abusers. In brief,
tissues were homogenized with a glass‐teflon homogenizer in ice‐
cold potassium phosphate buffer pH 7.4, and centrifuged 20 minute
at 9000g. The S9 fraction was centrifuged 60 minute at 100 000g to
obtain a microsomal pellet which was resuspended, further homoge-
nized, centrifuged, and resuspended in buffer containing 20% glyc-
erol24,25 for storage at −80°C. Total brain protein concentrations
were determined using Bio‐Rad Protein Assay Dye Regent Concen-
trate which is based on Bradford method. Results were expressed as
fmol min−1 mg−1 of total brain protein, as CYP2B6 protein was not
detectable.
2.1 | Cytochrome P450 and b5 concentration and
POR activity determination
All assays for P450 content, b5 content, and POR activity were car-
ried out using a Synergy MX Microplate Reader (Biotek, Winooski,
VT). Total protein concentrations were determined using Bio‐Rad
F IGURE 1 Nicotine metabolism
pathways
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Protein Assay Dye Regent Concentrate which is based on Bradford
method. P450 concentration was determined by difference spectrum
of ferrous‐carbon monoxide complex in a CO binding assay (reduced
vs reduced CO) using an extinction coefficient De450-490 nm of
91 mmol L−1 cm−1. Cytochrome b5 content was determined by dif-
ference spectrum of NADH‐reduced and oxidized b5 using an extinc-
tion coefficient De424-410 nm of 185 m mol L
−1 cm−1.
P450 oxidoreductase activity was measured by NADPH‐cyto-
chrome c reductase activity. To 200 μL of diluted cell lysate in
0.3 mol L−1 potassium phosphate buffer at pH 7.7 containing
40 μmol L−1 cytochrome c, 100 μmol L−1 NADPH was added to ini-
tiate the reduction of cytochrome c and the reaction was followed
at 550 nm and 23°C. The reaction rate was calculated using an
extinction coefficient of e550 nm of 21 mmol L
−1 cm−1 for reduced
cytochrome c. POR activity was converted to POR content based on
the assumption that 3000 nmol of cytochrome c is reduced/min per
nmol POR at 23°C.17,26
2.2 | Substrate metabolism
All incubations were carried out in 96‐well PCR plates in 50 μL
total volume at 37°C, as previously described.8 Incubations with
recombinant CYP2B6/POR/b5 proceeded for 10 minutes and incu-
bations with human brain microsomes proceeded for 1 hour, unless
otherwise noted, following a 2‐minute preincubation and initiation
with 25, 50, 100, 250, 500, 1000, 1,500, or 2,000 μmol L−1 S‐nico-
tine or R‐nicotine (Toronto Research Chemicals, Toronto, Canada)
in the presence of 1 mmol L−1 NADPH (Sigma‐Aldrich, St. Louis,
MO). Inhibition of metabolite formation was tested at 100 μmol
L−1 nicotine for convenience to ensure metabolite concentrations
remained within the concentration curve after incubation of up to
6 hours. Reactions were quenched by adding 10 μL 15% zinc sul-
fate containing 200 ng mL−1 of the internal standard, (d3)‐nicotine‐
N‐oxide (Toronto Research Chemicals, Toronto, Canada). Samples
were centrifuged and supernatants were removed for LC/MS
analysis.
Methadone incubations were performed with 10 μmol L−1
methadone and processed and analyzed as previously described.21,27
In brief, methadone was from the National Institute on Drug Abuse
(Bethesda, MD); all other reagents were purchased from Sigma‐
Aldrich. Reactions were quenched with 40 μl 20% trichloroacetic
acid containing internal standard (d3‐EDDP), and centrifuged for
5 minutes at 2500g; the supernatant was processed by solid phase
extraction as previously described,28,29 except that for Strata‐X‐C
33‐μm, 30 mg/well plates (Phenomenex, Torrance, CA) were used.
Analysis was performed on a Sunfire C18 column (2.1 × 50 mm,
3.5‐μm) (Waters, Milford, MA) with a 2‐μm column filter guard
(Supleco Analytical, Bellefonte, PA). Sample injections were 25 μL
and the column oven was held at 30°C. Mobile phase A was
4.5 mmol L−1 ammonium acetate in Milli‐Q water, pH 4.5, and
mobile phase B was 4.5 mol L−1 ammonium acetate in acetonitrile.
The mobile phase gradient (0.4 mL min−1) was 25% B for 0.5 min-
utes, linear gradient to 75% B between 0.5 and 4.2 minutes, held at
75% B until 5.0 minutes, immediately decreased back to 25% B and
re‐equilibrated at initial conditions for 3.0 minutes.
Ketamine incubations were performed with 80 μmol L−1 keta-
mine, and processed and analyzed as previously described17 In brief,
the reactions were quenched with 20% trichloroacetic acid
containing norketamine‐d4. The plate was centrifuged at 900 g for
5 minutes and the supernatant was subjected to solid phase extrac-
tion.30 Analytes were eluted with methanol and evaporated to dry-
ness under nitrogen. For analysis, samples were resuspended in
mobile phase (10 mmol L−1 ammonium acetate, pH 7.6). High perfor-
mance liquid chromatography (HPLC)‐mass spectrometry analysis
was performed on an ultra‐fast liquid chromatography system
(Shimadzu Scientific Instruments, Columbia, MD) with a CMB‐20A
system controller, two LC‐20ADXR pumps, DGU‐20A3 degasser,
SIL‐20AC autosampler, FCV‐11AL solvent selection module, and
CTO‐20A column oven (30°C) containing a ChiralPak AGP analytical
column (100 × 2.0 mm, 5 μm) and AGP guard column (10 × 2.0 mm)
(Chiral Technologies, West Chester, PA), coupled to an API 4000
QTrap LC‐MS/MS linear ion trap triple quadrupole tandem mass
spectrometer (Applied Biosystems/MDS Sciex, Foster City, CA). The
mobile phase (0.22 mL min−1) was 10 mmol L−1 ammonium acetate
in water, pH 7.60 (A) and isopropanol (B). The column was equili-
brated with 4% B, maintained after injection for 0.1 minute, then a
linear gradient to 16.8% B applied over 12 minutes, and then
reverted back to 4% B over 0.5 minute and re‐equilibrated for
3.5 minutes.
2.3 | Liquid chromatography tandem mass
spectrometry of nicotine metabolites
Nicotine metabolites were analyzed by liquid chromatography tan-
dem mass spectrometry (LC‐MS\MS) based on previous methods8
and quantified using the ratio of metabolite to internal standard,
subtracting background from control incubations (without NADPH),
and using calibration curves. The subtraction of control (NADPH‐)
incubations was necessary to subtract trace nicotine metabolites
present in the substrate, nicotine. Three replicates were performed
for each incubation. Further control incubations for brain micro-
somes included with boiled protein or without protein.
Liquid chromatography tandem mass spectrometry analyses were
performed on an API 4000 Q‐TRAP triple quadrupole mass spec-
trometer (Applied Biosystems Sciex, Foster City, CA) equipped with
an electrospray source. The HPLC system consisted of two LC 20AC
pumps with a CTO‐20A column oven, SIL‐20A autosampler, DGU‐
20A3 degasser, FCF‐11AL valve, and a CBM 20A controller (Shi-
madzu, Columbia, MD). The chromatographic separation was per-
formed on an xBridge column (150 × 2.1, 3.5 μm, Waters, Milford,
MA) with an inline precolumn 0.2 μm filter. The injection volume
was 5 μL and the oven temperature was 40°C. Mobile phase (0.3 mL
min−1) was (A) 4.5 mmol L−1 ammonium acetate pH 4.0 and (B)
4.5 mmol L−1 ammonium acetate in acetonitrile using the following
program: 1% B for 4 minutes, linear gradient to 25% B between 4
and 5 minutes, held at 25% B until 6.0 minutes, and then
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re‐equilibrated to initial conditions between 6.5 and 8.5 minutes.
Under these conditions, the retention times for nicotine iminium and
nornicotine (a minor CYP2B6 nicotine metabolite9) were 2.5 and
3.7 minutes, respectively; for cis and trans nicotine‐N‐oxide, they
were 4.7 and 5.2 minutes, respectively. The instrument was operated
in positive‐ion mode at 450°C with an ion spray voltage of 5500 V,
entrance potential of 10 V, and exit potential of 22 V. The curtain
gas was set at 20, ion source gas 1 at 30, and ion source gas 2 at
40. Transitions monitored for nicotine iminium were m/z 161 → 130,
for nornicotine, m/z 149 → 117, for nicotine‐N‐oxide m/z
179 → 132, and for deuterated (d3)‐nicotine‐N‐oxide, m/z
182 → 132.
2.4 | Statistical analysis
Michaelis‐Menten parameters for recombinant enzyme experiments
were determined by nonlinear regression using SigmaPlot (Systat
Software, San Jose, CA).
3 | RESULTS
3.1 | Nicotine oxidation by variant recombinant
CYP2B6 enzymes
Nine recombinant versions of the CYP2B6 enzymes, representing
common CYP2B6 haplotypes, were expressed to assess their relative
nicotine metabolism activities. Two nicotine metabolites were mea-
sured, nicotine iminium ion and nornicotine, with Km and Vmax
parameters determined for both metabolites for each variant
(Table 1). Our results confirm the role of CYP2B6 in nornicotine for-
mation.9 As expected, the activity of the most common variant
enzyme, CYP2B6.6, was lower than the reference allele enzyme,
CYP2B6.1, regarding both nicotine iminum (Clint = 1.9 vs 3.2 μL
min−1 nmol−1) and nornicotine (Clint = 0.5 vs 1.0 μL min−1 nmol−1)
(Figure 2).
Variation in CYP2B6 affects enzyme activity differently depend-
ing on substrate, which may include differences between isomers of
the same molecule. Nicotine occurs in two isomers, though approxi-
mately 99% of naturally occurring nicotine derived from tobacco and
other plants is the (S) isomer. In order to determine if effects on
CYP2B6 nicotine metabolism activity were also enantiomer‐specific,
incubations with four CYP2B6 haplotypes were repeated with (R)‐
nicotine (Table 2). Km and Vmax parameters were different for (R)‐
nicotine and (S)‐nicotine, but differences between CYP2B6 variants
appear consistent, that is, the activity of CYP2B6.6, was again lower
than the reference allele enzyme for nicotine iminum (Clint = 0.8 vs
1.8 μL−1 min−1 nmol−1) and nornicotine (Clint = 0.1 vs 0.2 μL−1
min−1 nmol−1). Interestingly, the regioselectivity of the enzyme, that
is, the metabolite ratio of nicotine iminium ion vs nornicotine, was
relatively consistent among different CYP2B6 variants, but differed
between (S)‐ and (R)‐nicotine (Tables 1 and 2).
3.2 | CYP2B6 substrate metabolism by human brain
microsomes
Microsomes were prepared from the cerebral cortices of six post-
mortem individuals. Nicotine‐N‐oxidation by FMO enzymes was used
as a positive control for tissue quality because FMO enzyme activity
is diminished by heat treatment at room temperature or repeated
freeze‐thawing. Nicotine‐iminium, but not nornicotine, was detected
in incubations with all six samples. In the presence of 100 μmol L−1
nicotine, the average turnover was 264 ± 133 (range 142‐498) fmol
min−1 mg−1 of microsomal protein. Activity was not significantly cor-
related with age (mean 72.9 ± 11.6 years) or postmortem interval
(mean 11.6 ± 3.1 hours). The activity remained linear for at least
6 hours (Figure 3). Incubation conditions were interrogated to





















*1 269 ± 37 0.85 ± 0.04 0.0032 184 ± 27 0.19 ± 0.01 0.0010 0.33
*4 K262R 333 ± 32 0.83 ± 0.03 0.0025 167 ± 28 0.21 ± 0.01 0.0013 0.50
*5 R487C 257 ± 22 0.66 ± 0.01 0.0026 132 ± 18 0.09 ± 0.00 0.0007 0.27
*6 Q172H/K262R 307 ± 16 0.58 ± 0.01 0.0019 110 ± 15 0.06 ± 0.00 0.0005 0.29
*7 Q172H/K262R/
R487C
236 ± 21 0.56 ± 0.01 0.0024 108 ± 23 0.09 ± 0.00 0.0008 0.35
*9 Q172H 406 ± 44 0.18 ± 0.01 0.0004 134 ± 21 0.02 ± 0.00 0.0001 0.34
*17 T26S/D28G/R29T 332 ± 22 0.85 ± 0.02 0.0026 130 ± 17 0.11 ± 0.00 0.0008 0.33
*19 Q172H/K262R/
R336C
271 ± 27 0.60 ± 0.02 0.0022 114 ± 26 0.06 ± 0.00 0.0005 0.24
*26 P167A/Q172H/
K262R
189 ± 21 0.41 ± 0.01 0.0022 86 ± 20 0.08 ± 0.00 0.0009 0.43
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determine whether iminium production was consistent with cyto-
chrome P450 activity. The activity was abolished by heat‐treatment
(65°C 1 hour), but did not require NADPH, and was not inhibited by
NADP (2 mmol L−1) or carbon monoxide treatment. Nicotine‐N‐
oxide, the product of FMO enzymes (Figure 1), was also detected in
the microsome incubations, but its formation required NADPH. On
further characterizing one brain, we found the NADPH‐independent
nicotine‐iminium formation did not follow Michaelis‐Menten kinetics
(Figure 4). Cotinine and hydroxycotinine were also not generated in
any human brain incubation.
To further investigate possible CYP2B6 activity in human brain
microsomes, we incubated them with two additional common
CYP2B6 probe substrates, methadone (10 μmol L−1) and ketamine
(80 μmol L−1), the approximate Km for CYP2B6 for each sub-
strate.27,31 Neither 2‐ethylidene‐1,5‐dimethyl‐3,3‐diphenylpyrrolidine
(EDDP) nor norketamine were detected, respectively.
4 | DISCUSSION
Extensive evidence demonstrates that functional variation in cyto-
chrome P450 genes can significantly affect the metabolism of many
small molecules including pharmaceuticals and toxins. Importantly,
common functional polymorphisms in CYP2B6 alter enzyme activity
in a substrate‐dependent manner,15,16,19,22,23,32-34 and thus it is
important to evaluate these enzyme variants for any CYP2B6
substrate. Here, we demonstrate how these common variants also
affect nicotine metabolism in vitro. The differences we report, both
for (S)‐nicotine and (R)‐nicotine, confirm the expectation of altered
activities for common variants including CYP2B6.6 and CYP2B6.9,
relative to the reference allele enzyme, CYP2B6.1. Because (S)‐nico-
tine is the common naturally occurring form of nicotine relevant to
smoking behavior, experiments with (R)‐nicotine were only per-
formed to explore substrate specificity and stereoselectivity. The
activities of the nine enzyme variants also differed with regard to
the relative metabolite ratios of (S)‐nicotine iminium and (S)‐nornico-
tine. The differences in this ratio demonstrate altered regioselectivity
associated with each polymorphism, that is, changes in the activity
of each enzyme isoform depend on which region of the substrate
molecule the enzyme oxidizes,35 resulting in the formation of nico-
tine iminum vs nornicotine.
Of particular interest are the differences in activity related to the
two amino acid changes, Q172H and K262R, which individually
define the CYP2B6*9 and CYP2B6*4 variants respectively, and
together define the very common CYP2B6*6 haplotype. For most
substrates, activity of the CYP2B6.9 variant is exceptionally low,
activity of the CYP2B6.4 variant is similar or greater than that of the
reference allele, while the activity of CYP2B6.6 lies between
CYP2B6.4 and CYP2B6.9, depending on substrate.14,21,22 This
demonstrates that the K262R amino acid change can partially com-
pensate for the Q172H loss‐of‐function, depending on substrate,
and we find this to be the case for nicotine as well. CYP2B6*6 is the
most commonly studied variant haplotype because of its high popu-
lation frequency and has been associated with low activity
in vivo.16,33 However, it is also important to note that part of this
loss of activity may be due to differences in mRNA or protein
expression or splicing, and not strictly related to catalytic activ-
ity.10,36,37 CYP2B6*6 (and CYP2B6*9) have also been reportedly asso-
ciated with more rapid in vivo nicotine metabolism.34
We previously demonstrated that common CYP2B6 haplotypes,
including missense variants and noncoding variants that affect gene
splicing, are associated with differences in in vivo nicotine metabo-
lism.10 However, the small contribution of CYP2B6 to hepatic nico-
tine metabolism38 is unlikely to influence smoking behaviors.
CYP2B6 mRNA expression has been reported in human brain,12
although direct evidence of CYP2B6 activity in brain tissue was not
previously demonstrated. It has therefore been suggested that
genetically determined variation in CYP2B6 activity in extrahepatic





















F IGURE 2 Intrinsic clearance (CLint) of (S)‐nicotine to nicotine
iminium ion and nornicotine by variant recombinant CYP2B6
enzymes

















*1 1537 ± 352 2.78 ± 0.24 0.0018 1288 ± 289 0.25 ± 0.03 0.0002 0.11
*4 K262R 1602 ± 436 2.11 ± 0.32 0.0013 936 ± 314 0.15 ± 0.02 0.0002 0.11
*6 Q172H/K262R 918 ± 409 0.73 ± 0.15 0.0008 956 ± 584 0.07 ± 0.02 0.0001 0.10
*9 Q172H 5040 ± 2276 0.72 ± 0.25 0.0001 1435 ± 665 0.03 ± 0.01 0.0000 0.13
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tissues might influence smoking behavior by altering local nicotine
levels in the brain.13 We recently demonstrated nicotine‐N‐oxidation
by flavin‐containing monoxygenases in microsomes prepared from
human brain.8 This provided an opportunity to further investigate
possible cytochrome P450‐related nicotine metabolism in post-
mortem samples known to retain detectable microsomal enzyme
activity. Given the difficulty of obtaining postmortem human brain
material, it was important to have a positive control for tissue qual-
ity. Postmortem intervals before initial freezing were typically
12 hours or more, and FMO activity is also subject to degradation at
room temperature and following repeated freeze‐thawing.
Interestingly, we found nicotine iminium ion produced in the pres-
ence of human brain microsomes (nornicotine was not detected), but
the mechanism of this weak activity was obscure. It is independent of
the cofactor NADPH and not inhibited by either carbon monoxide or
NADP, though the activity was abolished by heat treatment of the
microsomes. Meanwhile, the production of nicotine‐N‐oxide in the
same incubations required NADPH and was inhibited by carbon
monoxide, NADP, and heat treatment, as expected. We therefore con-
clude that the iminium ion detected was not due to cytochrome
P450s or any typical enzymatic activity. NADP and carbon monoxide
are general inhibitors of CYP enzymes. Had either general inhibitor
abolished the activity, we would have pursued other specific inhibitors
to narrow down the source of the activity to specific enzymes. Given
the high Km of CYP2B6 for nicotine, we further probed human brain
microsomes with two common CYP2B6 substrates, ketamine and
methadone, and found no evidence of metabolism of either.
Variation in local nicotine metabolism in the brain is ultimately
interesting because of the potential for targeting these pathways to
aid smoking cessation. Our prior work suggested that differences in
nicotine metabolism within the brain might influence nicotine depen-
dence in ways qualitatively different from the influence of hepatic
metabolism; namely, common functional variation in an enzyme
active in both liver and brain, FMO3, is associated with a significant
difference in nicotine dependence independent of cigarette consump-
tion level. Meanwhile, variation in the primary cytochrome‐P450‐
mediated nicotine metabolism pathway affects consumption among
dependent smokers but not liability to become dependent.8,39 It was
therefore important to understand whether the divergent influences
of these two pathways are related to inherent differences in their
activities—that is, the metabolites produced—or differences in their
tissue distributions. If the highly polymorphic CYP enzymes responsi-
ble for nicotine C‐oxidation were active in brain, it would argue
against FMO3's local brain activity being the mechanism of its
unique influence on dependence. Unlike CYP2A6, CYP2B6 mRNA
expression has been reported in human brain tissue, but aside from
its role in bupropion metabolism, genetic variation in CYP2B6 has
not been associated with smoking phenotypes. However, given the
well‐documented substrate specificity of functional variation in
CYP2B6, it was also necessary to determine which variants affect
nicotine metabolism, a question not previously addressed in vitro. A
key limitation of our study was the problem of enzymatic stability in
postmortem brain tissue. Nevertheless, if undetected CYP2B6 activ-
ity does occur in the human brain, with the potential to influence
smoking behavior in a similar manner to FMO3, associations
between CYP2B6 genotype and nicotine dependence should be
detectable in human genetic studies based on our in vitro activity
results together with previously published findings regarding varia-
tion in CYP2B6 expression.
In summary, we conclude that nicotine metabolism by CYP2B6 is
stereoselective, and common polymorphisms in CYP2B6 significantly
influence the oxidation of both (S) and (R)‐nicotine to nicotine imi-
nium and nornicotine. However, the small contribution of CYP2B6
to nicotine metabolism in the liver, and its undetectable activity in
human brain tissue, make it highly unlikely that this genetic variation
influences complex smoking behaviors.















F IGURE 3 Nicotine iminum formation over time in the presence
of human brain microsomes (HBMs), with and without NADPH,
inhibited by NADP or following carbon monoxide (CO) treatment























F IGURE 4 Nicotine iminum ion formed per mg human brain
microsomal protein per minute
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